trial summary · NCT07845825
Aprepitant for the Treatment of CLIFAHDD
Channeling Hope Trial 1: A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) of Chronic Aprepitant Use in Individuals With Congenital Contractures of the Limbs and Face, Hypotonia, and Development Delay (CLIFAHDD)
Trial record from the TrialBase DB dataset, status RECRUITING, condition CLIFAHDD, sponsored by The University of Texas Health Science Center at San Antonio. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
There are no drug treatments for individuals with Congenital Contractures of the Limb and Face, Hypotonia, and Developmental Delay (CLIFAHDD), an ultra-rare and severe neurodevelopmental disease. The investigators have learned more about the cause of the disease and researched possible treatments based on both the cause of the disease and the way certain drugs work. The investigators are interested in understanding the safety of using aprepitant (a drug already approved by the United States Food \& Drug Administration \[FDA\] to treat nausea and vomiting for kids and adults who are receiving chemotherapy) on people diagnosed with CLIFAHDD. The overall goal of this Phase 1 study is to study whether this drug is safe for daily use in individuals with CLIFAHDD and to find more information on how it impacts daily functioning and quality of life. The total study will take around 8 months total. This includes the 90 days before the drug starts and the 21 days after the drug ends.
Source record: https://clinicaltrials.gov/study/NCT07845825
Facts
| registry id | NCT07845825 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | EARLY_PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | CLIFAHDD |
| sponsor | The University of Texas Health Science Center at San Antonio |
| sponsor class | OTHER |
| enrollment | 5 |
| start date | 2026-10-31 |
| primary completion | 2027-05-31 |
| completion | 2027-07-31 |
| results posted | not reported |
Conditions
- CLIFAHDD
- Congenital Contractures of the Limbs and Face, Hypotonia, and Developmental Delay
- NALCN Channelopathy
- Ataxia - Other
- Neurodevelopmental Disorder (Diagnosis)
Interventions
- Aprepitant Powder for Oral Suspension
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.